title: Neuropharmacological effect of Mangiferin on brain cholinesterase and brain biogenic amines in the management of Alzheimer's disease.
abstract: The present study was conducted to evaluate the neuropharmacological effect of Mangiferin on brain cholinesterase and brain biogenic amines along with its antioxidant status. Scopolamine and natural aging were employed as an experimental amnesia inducing agents. The tested dose of Mangiferin (40, 20 and 10 mg/kg) significantly improved the learning ability and retention of learned memory in Elevated plus Maze and Passive Shock Avoidance exteroceptive behavioural models. Pre-treatment with Mangiferin restored increased whole brain acetylcholinestrease, lipid peroxidation and reduced glutathione due to scopolamine and natural aging. Whole brain increased dopamine and nor-adrenaline content in brain in the inducing groups were reversed by tested doses of Mangiferin insignificantly. Moreover the cerebroprotective effect of Mangiferin was well supported by photomicrographs of Hippocampus of brain, where as severity of cell damage, number of pyknotic black neurons, formation of karyorrhexis, karyolysis and number of neuronal cell death were less comparative to scopolamine group. The observed effects of Mangiferin claim that it would be worthwhile to utilize in the treatment of Alzheimer's disease.
authors.affiliation: Department of Pharmacology, Postgraduate Studies and Research Centre, SET's College of Pharmacy, Dharwad-580 002, India. smbiradar@rediffmail.com
authors.forename: Siddaruda M
authors.initials: SM
authors.lastname: Biradar
authors.forename: Hanumanthachar
authors.initials: H
authors.lastname: Joshi
authors.forename: Tarak K
authors.initials: TK
authors.lastname: Chheda
mesh_terms: D000110:Acetylcholinesterase / Q000378:metabolism*; D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D016923:Cell Death / Q000187:drug effects; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D058851:GPI-Linked Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D015227:Lipid Peroxidation / Q000187:drug effects; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009638:Norepinephrine / Q000378:metabolism*; D044004:Xanthones / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D002800:Cholinesterase Inhibitors; D058851:GPI-Linked Proteins; D009419:Nerve Tissue Proteins; D018697:Nootropic Agents; D044004:Xanthones; C013592:mangiferin; D000110:Acetylcholinesterase; C548245:Ache protein, mouse; D005978:Glutathione; D004298:Dopamine; D009638:Norepinephrine